English
Cost-Effectiveness
/assets/ct/2fee4a8a5e/images/syn_placeholder_sqr.png

Cost-Effectiveness

Clinical research has shown that, on average, the use of evidence-based treatment strategies that preempt blood transfusion leads to comparable or superior outcomes at similar or reduced cost. The true cost of allogeneic blood transfusions includes direct costs (such as donor recruitment, screening, collection, processing, testing, storage, distribution, disposal of unused inventory, and hemovigilance programs) as well as indirect costs (such as hospital-acquired infections, cancer recurrence, longer hospital stays, and increased hospital mortality). Clinicians can provide safe, cost-effective, evidence-based, quality medical care without dependence on allogeneic blood transfusion.